Analystreport

Health Catalyst (NASDAQ: HCAT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $44.00 price target on the stock.

Health Catalyst, Inc - Common stock  (HCAT) 
Last health catalyst, inc - common stock earnings: 2/27 04:05 pm Check Earnings Report